-
Je něco špatně v tomto záznamu ?
Vasopressin in Patients with Septic Shock and Dynamic Left Ventricular Outflow Tract Obstruction
M. Balik, A. Novotny, D. Suk, V. Matousek, M. Maly, T. Brozek, G. Tavazzi,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- agonisté adrenergních receptorů terapeutické užití MeSH
- arginin vasopresin terapeutické užití MeSH
- dýchání účinky léků MeSH
- funkce levé komory srdeční účinky léků MeSH
- hemodynamika účinky léků MeSH
- incidence MeSH
- lidé středního věku MeSH
- lidé MeSH
- noradrenalin terapeutické užití MeSH
- obnova funkce MeSH
- obstrukce výtoku ze srdeční komory diagnostické zobrazování farmakoterapie epidemiologie patofyziologie MeSH
- senioři MeSH
- septický šok diagnostické zobrazování farmakoterapie epidemiologie patofyziologie MeSH
- stupeň závažnosti nemoci MeSH
- vazokonstriktory terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
PURPOSE: Left ventricular outflow tract obstruction (LVOTO) is a relatively uncommon but severe condition that may lead to hemodynamic impairment. It can be elicited by morphological (left ventricular hypertrophy, sigmoid septum, prominent papillary muscle, prolonged anterior mitral valve leaflet) and functional (hypovolemia, low afterload, hypercontractility, catecholamines) factors. We sought to determine the incidence of the most severe form of LVOTO in septic shock patients and describe the therapeutic effects of vasopressin. METHODS: Over a period of 29 months, 527 patients in septic shock were screened for LVOTO. All were mechanically ventilated and treated according to sepsis bundles, including pre-load optimization and norepinephrine infusion. Vasopressin was added in addition to norepinephrine to reduce the adrenergic burden and decrease LVOTO. RESULTS: Ten patients were diagnosed with the most severe form of LVOTO, including systolic anterior mitral valve motion (SAM) and severe mitral regurgitation (MR) with pulmonary oedema. The median norepinephrine dosage to obtain a mean arterial pressure of ≥70 mmHg was 0.58 mcg/Kg/min (IQR 0.40-0.78). All patients had a hyper-contractile left ventricle, septal hypertrophy, significant LVOTO (peak gradient 78 [56-123] mmHg) associated with SAM and severe MR with pulmonary oedema. Vasopressin (median 4 IU/h) allowed a significant reduction of norepinephrine (0.18 [0.14-0.30] mcg/kg/min; p = 0.01), LVOT gradient (35 [24-60] mmHg; p = 0.01) and MR with a significant paO2/FiO2 increase (174 [125-213] mmHg; p = 0.01). CONCLUSION: Vasopressin allowed a reduction of norepinephrine with subsequent LVOTO reduction and hemodynamic improvement of the most severe form of LVOTO, which represented 1.9% of all septic shock patients.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20027762
- 003
- CZ-PrNML
- 005
- 20210608133910.0
- 007
- ta
- 008
- 210105s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10557-020-06998-8 $2 doi
- 035 __
- $a (PubMed)32488425
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Balik, Martin $u Department of Anesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague 2, 128 08, Czechia. martin.balik@vfn.cz.
- 245 10
- $a Vasopressin in Patients with Septic Shock and Dynamic Left Ventricular Outflow Tract Obstruction / $c M. Balik, A. Novotny, D. Suk, V. Matousek, M. Maly, T. Brozek, G. Tavazzi,
- 520 9_
- $a PURPOSE: Left ventricular outflow tract obstruction (LVOTO) is a relatively uncommon but severe condition that may lead to hemodynamic impairment. It can be elicited by morphological (left ventricular hypertrophy, sigmoid septum, prominent papillary muscle, prolonged anterior mitral valve leaflet) and functional (hypovolemia, low afterload, hypercontractility, catecholamines) factors. We sought to determine the incidence of the most severe form of LVOTO in septic shock patients and describe the therapeutic effects of vasopressin. METHODS: Over a period of 29 months, 527 patients in septic shock were screened for LVOTO. All were mechanically ventilated and treated according to sepsis bundles, including pre-load optimization and norepinephrine infusion. Vasopressin was added in addition to norepinephrine to reduce the adrenergic burden and decrease LVOTO. RESULTS: Ten patients were diagnosed with the most severe form of LVOTO, including systolic anterior mitral valve motion (SAM) and severe mitral regurgitation (MR) with pulmonary oedema. The median norepinephrine dosage to obtain a mean arterial pressure of ≥70 mmHg was 0.58 mcg/Kg/min (IQR 0.40-0.78). All patients had a hyper-contractile left ventricle, septal hypertrophy, significant LVOTO (peak gradient 78 [56-123] mmHg) associated with SAM and severe MR with pulmonary oedema. Vasopressin (median 4 IU/h) allowed a significant reduction of norepinephrine (0.18 [0.14-0.30] mcg/kg/min; p = 0.01), LVOT gradient (35 [24-60] mmHg; p = 0.01) and MR with a significant paO2/FiO2 increase (174 [125-213] mmHg; p = 0.01). CONCLUSION: Vasopressin allowed a reduction of norepinephrine with subsequent LVOTO reduction and hemodynamic improvement of the most severe form of LVOTO, which represented 1.9% of all septic shock patients.
- 650 _2
- $a agonisté adrenergních receptorů $x terapeutické užití $7 D000322
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a arginin vasopresin $x terapeutické užití $7 D001127
- 650 _2
- $a hemodynamika $x účinky léků $7 D006439
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a noradrenalin $x terapeutické užití $7 D009638
- 650 _2
- $a obnova funkce $7 D020127
- 650 _2
- $a dýchání $x účinky léků $7 D012119
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a septický šok $x diagnostické zobrazování $x farmakoterapie $x epidemiologie $x patofyziologie $7 D012772
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a vazokonstriktory $x terapeutické užití $7 D014662
- 650 _2
- $a funkce levé komory srdeční $x účinky léků $7 D016277
- 650 _2
- $a obstrukce výtoku ze srdeční komory $x diagnostické zobrazování $x farmakoterapie $x epidemiologie $x patofyziologie $7 D014694
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Novotny, Adam $u Department of Anesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague 2, 128 08, Czechia.
- 700 1_
- $a Suk, Daniel $u Department of Anesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague 2, 128 08, Czechia.
- 700 1_
- $a Matoušek, Vojtěch $u Department of Anesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague 2, 128 08, Czechia. $7 xx0260730
- 700 1_
- $a Maly, Michal $u Department of Anesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague 2, 128 08, Czechia.
- 700 1_
- $a Brozek, Tomas $u Department of Anesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague 2, 128 08, Czechia.
- 700 1_
- $a Tavazzi, Guido $u Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, Unit of Anaesthesia and Intensive Care Fondazione Policlinico San Matteo, IRCCS, University of Pavia, Pavia, Italy.
- 773 0_
- $w MED00001057 $t Cardiovascular drugs and therapy $x 1573-7241 $g Roč. 34, č. 5 (2020), s. 685-688
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32488425 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210608133907 $b ABA008
- 999 __
- $a ok $b bmc $g 1608097 $s 1118942
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 34 $c 5 $d 685-688 $e - $i 1573-7241 $m Cardiovascular drugs and therapy $n Cardiovasc Drugs Ther $x MED00001057
- LZP __
- $a Pubmed-20210105